![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="250" height="148"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
Session 7: Recent Advances in Antibody-Drug Conjugates for the Treatment of Cancer
1:20 PM – 2:30 PM
Moderator:
Marco Gottardis, PhD
Janssen Research & Development, LLC
Introduction
Marco Gottardis, PhD
Janssen Research & Development, LLC
Antibody Drug Conjugates: From Early Stage Research to Clinically Approved Drugs
Peter Senter, PhD
Seattle Genetics
Novel Approaches to Development of Antibody-Drug Conjugates for the Treatment of Cancer
Yuuri Hashimoto, PhD
Daiichi Sankyo Co., Ltd.
PSMA Antibody Targeted Amanitin Conjugate (PSMA-ATAC): Introducing a Novel Mode of Action into Prostate Cancer Therap
George Badescu, PhD
Heidelberg Pharma AG
Live Session Discussion
Friday, October 23, 2020